<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00316264</url>
  </required_header>
  <id_info>
    <org_study_id>MI-CP127</org_study_id>
    <nct_id>NCT00316264</nct_id>
  </id_info>
  <brief_title>Study of Motavizumab (MEDI-524) and Palivizumab Administered Sequentially in the Same Respiratory Syncytial Virus (RSV) Season</brief_title>
  <official_title>A Phase 2, Randomized, Double-Blind Study to Evaluate the Safety, Tolerability, and Immunogenicity of Motavizumab (MEDI-524), a Humanized Enhanced Potency Monoclonal Antibody Against Respiratory Syncytial Virus (RSV), and Palivizumab When Administered in the Same Season</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>MedImmune LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>MedImmune LLC</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase 2, randomized, double-blind study in which motavizumab (MEDI-524) and
      palivizumab were administered sequentially to high-risk children during the same respiratory
      syncytial virus (RSV) season. A control group was administered only motavizumab.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a Phase 2, randomized, double-blind study in which motavizumab and palivizumab were
      administered sequentially to high-risk children during the same RSV season. It was
      anticipated that approximately 240 children (80 in each group) would be enrolled from the
      southern hemisphere during the upcoming RSV season (2006). Children were randomized into one
      of three regimens in a 1:1:1 ratio; the first group received 2 doses of motavizumab followed
      by 3 doses of palivizumab; the second group received 2 doses of palivizumab followed by 3
      doses of motavizumab; and the third group received 5 doses of motavizumab. Motavizumab or
      palivizumab was administered at 15 mg/kg by IM injection every 30 days, for a total of 5
      injections.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2006</start_date>
  <completion_date type="Actual">February 2007</completion_date>
  <primary_completion_date type="Actual">February 2007</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Subjects Reporting Serious Adverse Events (SAEs)</measure>
    <time_frame>Day 0 - Day 150</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Subjects Reporting Adverse Events (AEs)</measure>
    <time_frame>Day 0 - Day 150</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Subjects With Changes in Laboratory Chemistry Values Reported as AEs.</measure>
    <time_frame>Day 0 - Day 150</time_frame>
    <description>Serum chemistry samples were collected at Day 0, Day 60, and Day 150. Values representing changes in severity according to the AE grading table were recorded as AEs.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The Serum Concentrations of Motavizumab at Day 0</measure>
    <time_frame>Day 0</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Trough Serum Concentrations of Motavizumab at Day 60</measure>
    <time_frame>Day 60</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Trough Serum Concentrations of Motavizumab at Day 150</measure>
    <time_frame>Day 150</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Trough Serum Concentrations of Motavizumab 120-150 Days Post Final Dose</measure>
    <time_frame>120-150 days post final dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Serum Concentrations of Palivizumab at Day 0</measure>
    <time_frame>Day 0</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Trough Serum Concentrations of Palivizumab at Day 60</measure>
    <time_frame>Day 60</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Trough Serum Concentrations of Palivizumab at Day 150</measure>
    <time_frame>Day 150</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Trough Serum Concentrations of Palivizumab at 120-150 Days Post Final Dose</measure>
    <time_frame>120-150 days post final dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Immunogenicity of Motavizumab at Day 0</measure>
    <time_frame>Day 0</time_frame>
    <description>Number of subjects with detected anti-motavivumab antibodies are reported; defined as a titer with a dilution value of greater than or equal to 1:10.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Immunogenicity of Motavizumab at Day 60</measure>
    <time_frame>Day 60</time_frame>
    <description>Number of subjects with detected anti-motavivumab antibodies are reported; defined as a titer with a dilution value of greater than or equal to 1:10.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Immunogenicity of Motavizumab at Day 150</measure>
    <time_frame>Day 150</time_frame>
    <description>Number of subjects with detected anti-motavivumab antibodies are reported; defined as a titer with a dilution value of greater than or equal to 1:10.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Immunogenicity of Motavizumab at 120 to 150 Days Post Final Dose</measure>
    <time_frame>120 - 150 days post final dose</time_frame>
    <description>Number of subjects with detected anti-motavivumab antibodies are reported; defined as a titer with a dilution value of greater than or equal to 1:10.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Immunogenicity of Motavizumab at Any Time</measure>
    <time_frame>At any time</time_frame>
    <description>Number of subjects with detected anti-motavivumab antibodies are reported; defined as a titer with a dilution value of greater than or equal to 1:10.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Immunogenicity of Palivizumab at Day 0</measure>
    <time_frame>Day 0</time_frame>
    <description>Number of subjects with detected anti-palivizumab antibodies are reported; defined as a titer with a dilution value of greater than or equal to 1:10.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Immunogenicity of Palivizumab at Day 60</measure>
    <time_frame>Day 60</time_frame>
    <description>Number of subjects with detected anti-palivizumab antibodies are reported; defined as a titer with a dilution value of greater than or equal to 1:10.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Immunogenicity of Palivizumab at Day 150</measure>
    <time_frame>Day 150</time_frame>
    <description>Number of subjects with detected anti-palivizumab antibodies are reported; defined as a titer with a dilution value of greater than or equal to 1:10.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Immunogenicity of Palivizumab at 120 to 150 Days Post Final Dose</measure>
    <time_frame>120 - 150 days post final pose</time_frame>
    <description>Number of subjects with detected anti-palivizumab antibodies are reported; defined as a titer with a dilution value of greater than or equal to 1:10.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Immunogenicity of Palivizumab at Any Time</measure>
    <time_frame>At any time</time_frame>
    <description>Number of subjects with detected anti-palivizumab antibodies are reported; defined as a titer with a dilution value of greater than or equal to 1:10.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">260</enrollment>
  <condition>Respiratory Syncytial Virus Infections</condition>
  <condition>Chronic Lung Disease and &lt;= 24 Months of Age or</condition>
  <condition>Premature With Gestational Age &lt;=35 Weeks and &lt;=6 Months of Age</condition>
  <arm_group>
    <arm_group_label>Motavizumab followed by Palivizumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>2 doses of motavizumab (15 mg/kg, administered as an intramuscular injection once/month) followed by 3 doses of palivizumab (15 mg/kg, administered as an intramuscular injection once/month)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Palivizumab followed by motavizumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>2 doses of palivizumab (15 mg/kg, administered as an intramuscular injection once/month) followed by 3 doses of motavizumab (15 mg/kg, administered as an intramuscular injection once/month)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Motavizumab control</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>5 doses of motavizumab (15 mg/kg, administered as an intramuscular injection once/month)</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Motavizumab, palivizumab</intervention_name>
    <description>Motavizumab was provided in sterile vials containing 100 mg of motavizumab in 1 mL of a sterile preservative-free liquid product at pH 6.0, formulated with 25 mM histidine-HCl.</description>
    <arm_group_label>Motavizumab followed by Palivizumab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Palivizumab, motavizumab</intervention_name>
    <description>Palivizumab was provided in sterile vials containing 100 mg of palivizumab in 1 mL of a sterile preservative-free liquid product at pH 6.0, formulated with 25 mM histidine, and 1.6 mM glycine.</description>
    <arm_group_label>Palivizumab followed by motavizumab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Motavizumab</intervention_name>
    <description>Motavizumab was provided in sterile vials containing 100 mg of motavizumab in 1 mL of a sterile preservative-free liquid product at pH 6.0, formulated with 25 mM histidine-HCl.</description>
    <arm_group_label>Motavizumab control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  The child must have been born at less than or equal to 35 weeks gestation and be less
             than or equal to 6 months of age at the time of entry into the study (child must be
             entered on or before his/her 6-month birthday); or the child must be less than or
             equal to 24 months of age at the time of entry into the study (child must be entered
             on or before his/her 24-month birthday) and diagnosed with chronic lung disease (CLD)
             of prematurity with stable or decreasing doses of diuretics, steroids, or
             bronchodilators, or treatment with supplemental oxygen, within the previous 6 months.

          -  The child must be in general good health at the time of study entry.

          -  The child's parent(s)/legal guardian must provide written informed consent.

          -  The child must be able to complete the follow-up visits through 120-150 days from last
             injection of study drug.

          -  Parent(s)/legal guardian of patient must have available telephone access.

        Exclusion Criteria:

          -  Hospitalized at the time of study entry (unless discharge is expected within 10 days
             after entry into the study)

          -  Receiving chronic oxygen therapy or mechanical ventilation at the time of study entry
             (including continuous positive airway pressure [CPAP])

          -  Congenital heart disease (CHD) (children with medically or surgically corrected
             [closed] patent ductus arteriosus and no other CHD may be enrolled)

          -  Evidence of infection with hepatitis A, B, or C virus

          -  Known renal impairment, hepatic dysfunction, chronic seizure disorder, or
             immunodeficiency or HIV infection (a child of a mother with known HIV infection must
             be proven to be uninfected at the time of enrollment)

          -  Suspected serious allergic or immune-mediated events with prior receipt of palivizumab

          -  Acute illness or progressive clinical disorder

          -  Active infection, including acute RSV infection, at the time of enrollment

          -  Previous reaction to intravenous immunoglobulin (IGIV), blood products, or other
             foreign proteins

          -  Received within the past 120 days or currently receiving immunoglobulin products (such
             as RSV-IGIV [RespiGam], IVIG, or palivizumab) or any investigational agents

          -  Previous participation in a clinical trial of motavizumab

          -  Currently participating in any investigational study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>24 Months</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pamela Griffin, M.D.</last_name>
    <role>Study Director</role>
    <affiliation>MedImmune LLC</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Paediatrics and Child Health, The Canberra Hospital</name>
      <address>
        <city>Garran</city>
        <state>Australian Capital Territory</state>
        <zip>2605</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Neonatalogy John Hunter Hospital</name>
      <address>
        <city>New Lambton Heights</city>
        <state>New South Wales</state>
        <zip>2305</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Caboolture Clinical Research</name>
      <address>
        <city>Caboolture</city>
        <state>Queensland</state>
        <zip>4510</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Queensland, Royal Children's Hospital</name>
      <address>
        <city>Herston</city>
        <state>Queensland</state>
        <zip>4029</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Peninsula Clinical Research Centre</name>
      <address>
        <city>Kippa-Ring</city>
        <state>Queensland</state>
        <zip>4021</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Women's and Children's Hospital</name>
      <address>
        <city>North Adelaide</city>
        <state>South Australia</state>
        <zip>5006</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Respiratory Medicine Department, Royal Children's Hospital</name>
      <address>
        <city>Parkville</city>
        <state>Victoria</state>
        <zip>3052</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clinico de la Universidad de Chile</name>
      <address>
        <city>Independencia</city>
        <state>Santiago</state>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital San Jose</name>
      <address>
        <city>Independencia</city>
        <state>Santiago</state>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clinico de la Pontificia Universidad Catolica de Chile</name>
      <address>
        <city>Santiago</city>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clinico San Borja Arriaran</name>
      <address>
        <city>Santiago</city>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Dr Felix Bulnes Cerda</name>
      <address>
        <city>Santiago</city>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Dr. Sotero del Rio</name>
      <address>
        <city>Santiago</city>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Padre Hurtado</name>
      <address>
        <city>Santiago</city>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kidz First, Middlemore Hospital</name>
      <address>
        <city>Otahuhu</city>
        <state>Auckland</state>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Christchurch Women's Hospital</name>
      <address>
        <city>Christchurch</city>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Paediatric Medicine, Dunedin Hospital</name>
      <address>
        <city>Dunedin</city>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Paediatrics, Waikato Hospital</name>
      <address>
        <city>Hamilton</city>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Child Health, Palmerston North Hospital</name>
      <address>
        <city>Palmerston North</city>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Chile</country>
    <country>New Zealand</country>
  </location_countries>
  <removed_countries>
    <country>Brazil</country>
  </removed_countries>
  <results_reference>
    <citation>Fernández P, Trenholme A, Abarca K, Griffin MP, Hultquist M, Harris B, Losonsky GA; Motavizumab Study Group. A phase 2, randomized, double-blind safety and pharmacokinetic assessment of respiratory syncytial virus (RSV) prophylaxis with motavizumab and palivizumab administered in the same season. BMC Pediatr. 2010 Jun 3;10:38. doi: 10.1186/1471-2431-10-38.</citation>
    <PMID>20525274</PMID>
  </results_reference>
  <verification_date>November 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 18, 2006</study_first_submitted>
  <study_first_submitted_qc>April 18, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 20, 2006</study_first_posted>
  <results_first_submitted>October 3, 2012</results_first_submitted>
  <results_first_submitted_qc>November 13, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">December 11, 2012</results_first_posted>
  <last_update_submitted>November 13, 2012</last_update_submitted>
  <last_update_submitted_qc>November 13, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 11, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Respiratory Syncytial Virus</keyword>
  <keyword>Premature and under 6 mos. of age</keyword>
  <keyword>Chronic Lung Disease over 6 mos. of age</keyword>
  <keyword>palivizumab</keyword>
  <keyword>motavizumab</keyword>
  <keyword>RSV</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Virus Diseases</mesh_term>
    <mesh_term>Respiratory Syncytial Virus Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Palivizumab</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>It was anticipated that approximately 240 children (80 in each group) would be enrolled from the southern hemisphere during the upcoming RSV season (2006).</recruitment_details>
      <pre_assignment_details>Children were randomized into one of three regimens in a 1:1:1 ratio; the first group received 2 doses of motavizumab followed by 3 doses of palivizumab; the second group received 2 doses of palivizumab followed by 3 doses of motavizumab; and the third group received 5 doses of motavizumab.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Motavizumab (MEDI-524) Followed by Palivizumab</title>
          <description>2 doses of motavizumab (15 mg/kg, administered as an intramuscular injection once/month) followed by 3 doses of palivizumab (15 mg/kg, administered as an intramuscular injection once/month)</description>
        </group>
        <group group_id="P2">
          <title>Palivizumab Followed by Motavizumab (MEDI-524)</title>
          <description>2 doses of palivizumab (15 mg/kg, administered as an intramuscular injection once/month) followed by 3 doses of motavizumab (15 mg/kg, administered as an intramuscular injection once/month)</description>
        </group>
        <group group_id="P3">
          <title>Motavizumab (MEDI-524) Control</title>
          <description>5 doses of motavizumab (15 mg/kg, administered as an intramuscular injection once/month)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="83"/>
                <participants group_id="P2" count="84"/>
                <participants group_id="P3" count="93"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="77"/>
                <participants group_id="P2" count="77"/>
                <participants group_id="P3" count="87"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="7"/>
                <participants group_id="P3" count="6"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal of Consent</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>not specified</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Motavizumab (MEDI-524) Followed by Palivizumab</title>
          <description>2 doses of motavizumab (15 mg/kg, administered as an intramuscular injection once/month) followed by 3 doses of palivizumab (15 mg/kg, administered as an intramuscular injection once/month)</description>
        </group>
        <group group_id="B2">
          <title>Palivizumab Followed by Motavizumab (MEDI-524)</title>
          <description>2 doses of palivizumab (15 mg/kg, administered as an intramuscular injection once/month) followed by 3 doses of motavizumab (15 mg/kg, administered as an intramuscular injection once/month)</description>
        </group>
        <group group_id="B3">
          <title>Motavizumab (MEDI-524) Control</title>
          <description>5 doses of motavizumab (15 mg/kg, administered as an intramuscular injection once/month)</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="83"/>
            <count group_id="B2" value="84"/>
            <count group_id="B3" value="93"/>
            <count group_id="B4" value="260"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>months</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3.68" spread="3.13"/>
                    <measurement group_id="B2" value="3.35" spread="2.25"/>
                    <measurement group_id="B3" value="3.92" spread="2.43"/>
                    <measurement group_id="B4" value="3.66" spread="2.62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="32"/>
                    <measurement group_id="B2" value="41"/>
                    <measurement group_id="B3" value="45"/>
                    <measurement group_id="B4" value="118"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="51"/>
                    <measurement group_id="B2" value="43"/>
                    <measurement group_id="B3" value="48"/>
                    <measurement group_id="B4" value="142"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Subjects Reporting Serious Adverse Events (SAEs)</title>
        <time_frame>Day 0 - Day 150</time_frame>
        <population>The safety population included all randomized subjects who received study drug and had any safety follow-up.</population>
        <group_list>
          <group group_id="O1">
            <title>Motavizumab (MEDI-524) Followed by Palivizumab</title>
            <description>2 doses of motavizumab (15 mg/kg, administered as an intramuscular injection once/month) followed by 3 doses of palivizumab (15 mg/kg, administered as an intramuscular injection once/month)</description>
          </group>
          <group group_id="O2">
            <title>Palivizumab Followed by Motavizumab (MEDI-524)</title>
            <description>2 doses of palivizumab (15 mg/kg, administered as an intramuscular injection once/month) followed by 3 doses of motavizumab (15 mg/kg, administered as an intramuscular injection once/month)</description>
          </group>
          <group group_id="O3">
            <title>Motavizumab (MEDI-524) Control</title>
            <description>5 doses of motavizumab (15 mg/kg, administered as an intramuscular injection once/month)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Reporting Serious Adverse Events (SAEs)</title>
          <population>The safety population included all randomized subjects who received study drug and had any safety follow-up.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="83"/>
                <count group_id="O2" value="83"/>
                <count group_id="O3" value="93"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19"/>
                    <measurement group_id="O2" value="7"/>
                    <measurement group_id="O3" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Subjects Reporting Adverse Events (AEs)</title>
        <time_frame>Day 0 - Day 150</time_frame>
        <population>The safety population included all randomized subjects who received study drug and had any safety follow-up.</population>
        <group_list>
          <group group_id="O1">
            <title>Motavizumab (MEDI-524) Followed by Palivizumab</title>
            <description>2 doses of motavizumab (15 mg/kg, administered as an intramuscular injection once/month) followed by 3 doses of palivizumab (15 mg/kg, administered as an intramuscular injection once/month)</description>
          </group>
          <group group_id="O2">
            <title>Palivizumab Followed by Motavizumab (MEDI-524)</title>
            <description>2 doses of palivizumab (15 mg/kg, administered as an intramuscular injection once/month) followed by 3 doses of motavizumab (15 mg/kg, administered as an intramuscular injection once/month)</description>
          </group>
          <group group_id="O3">
            <title>Motavizumab (MEDI-524) Control</title>
            <description>5 doses of motavizumab (15 mg/kg, administered as an intramuscular injection once/month)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Reporting Adverse Events (AEs)</title>
          <population>The safety population included all randomized subjects who received study drug and had any safety follow-up.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="83"/>
                <count group_id="O2" value="83"/>
                <count group_id="O3" value="93"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="77"/>
                    <measurement group_id="O2" value="75"/>
                    <measurement group_id="O3" value="83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Subjects With Changes in Laboratory Chemistry Values Reported as AEs.</title>
        <description>Serum chemistry samples were collected at Day 0, Day 60, and Day 150. Values representing changes in severity according to the AE grading table were recorded as AEs.</description>
        <time_frame>Day 0 - Day 150</time_frame>
        <population>The safety population included all randomized subjects who received study drug and had any safety follow-up.</population>
        <group_list>
          <group group_id="O1">
            <title>Motavizumab (MEDI-524) Followed by Palivizumab</title>
            <description>2 doses of motavizumab (15 mg/kg, administered as an intramuscular injection once/month) followed by 3 doses of palivizumab (15 mg/kg, administered as an intramuscular injection once/month)</description>
          </group>
          <group group_id="O2">
            <title>Palivizumab Followed by Motavizumab (MEDI-524)</title>
            <description>2 doses of palivizumab (15 mg/kg, administered as an intramuscular injection once/month) followed by 3 doses of motavizumab (15 mg/kg, administered as an intramuscular injection once/month)</description>
          </group>
          <group group_id="O3">
            <title>Motavizumab (MEDI-524) Control</title>
            <description>5 doses of motavizumab (15 mg/kg, administered as an intramuscular injection once/month)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Changes in Laboratory Chemistry Values Reported as AEs.</title>
          <description>Serum chemistry samples were collected at Day 0, Day 60, and Day 150. Values representing changes in severity according to the AE grading table were recorded as AEs.</description>
          <population>The safety population included all randomized subjects who received study drug and had any safety follow-up.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="83"/>
                <count group_id="O2" value="83"/>
                <count group_id="O3" value="93"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Alanine aminotransferase increased</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hepatic enzyme increased</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Liver function test abnormal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Blood urea increased</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Aspartate aminotransferase increased</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Serum Concentrations of Motavizumab at Day 0</title>
        <time_frame>Day 0</time_frame>
        <population>The PK/immunogenicity population included all subjects in the safety population who did not receive commercial Synagis within 120 days prior to Study Day 0. Additional subjects were excluded from individual time point summaries of the analyses if the correct number of study drug doses were not received prior to the corresponding time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Motavizumab (MEDI-524) Followed by Palivizumab</title>
            <description>2 doses of motavizumab (15 mg/kg, administered as an intramuscular injection once/month) followed by 3 doses of palivizumab (15 mg/kg, administered as an intramuscular injection once/month)</description>
          </group>
          <group group_id="O2">
            <title>Palivizumab Followed by Motavizumab (MEDI-524)</title>
            <description>2 doses of palivizumab (15 mg/kg, administered as an intramuscular injection once/month) followed by 3 doses of motavizumab (15 mg/kg, administered as an intramuscular injection once/month)</description>
          </group>
          <group group_id="O3">
            <title>Motavizumab (MEDI-524) Control</title>
            <description>5 doses of motavizumab (15 mg/kg, administered as an intramuscular injection once/month)</description>
          </group>
        </group_list>
        <measure>
          <title>The Serum Concentrations of Motavizumab at Day 0</title>
          <population>The PK/immunogenicity population included all subjects in the safety population who did not receive commercial Synagis within 120 days prior to Study Day 0. Additional subjects were excluded from individual time point summaries of the analyses if the correct number of study drug doses were not received prior to the corresponding time point.</population>
          <units>μg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="76"/>
                <count group_id="O2" value="75"/>
                <count group_id="O3" value="85"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Values were below the level of detection.</measurement>
                    <measurement group_id="O2" value="NA">Values were below the level of detection.</measurement>
                    <measurement group_id="O3" value="NA">Values were below the level of detection.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Trough Serum Concentrations of Motavizumab at Day 60</title>
        <time_frame>Day 60</time_frame>
        <population>The PK/immunogenicity population included all subjects in the safety population who did not receive commercial Synagis within 120 days prior to Study Day 0. Additional subjects were excluded from individual time point summaries of the analyses if the correct number of study drug doses were not received prior to the corresponding time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Motavizumab (MEDI-524) Followed by Palivizumab</title>
            <description>2 doses of motavizumab (15 mg/kg, administered as an intramuscular injection once/month) followed by 3 doses of palivizumab (15 mg/kg, administered as an intramuscular injection once/month)</description>
          </group>
          <group group_id="O2">
            <title>Palivizumab Followed by Motavizumab (MEDI-524)</title>
            <description>2 doses of palivizumab (15 mg/kg, administered as an intramuscular injection once/month) followed by 3 doses of motavizumab (15 mg/kg, administered as an intramuscular injection once/month)</description>
          </group>
          <group group_id="O3">
            <title>Motavizumab (MEDI-524) Control</title>
            <description>5 doses of motavizumab (15 mg/kg, administered as an intramuscular injection once/month)</description>
          </group>
        </group_list>
        <measure>
          <title>The Trough Serum Concentrations of Motavizumab at Day 60</title>
          <population>The PK/immunogenicity population included all subjects in the safety population who did not receive commercial Synagis within 120 days prior to Study Day 0. Additional subjects were excluded from individual time point summaries of the analyses if the correct number of study drug doses were not received prior to the corresponding time point.</population>
          <units>μg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="67"/>
                <count group_id="O2" value="70"/>
                <count group_id="O3" value="72"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="74.74" spread="27.50"/>
                    <measurement group_id="O2" value="0.9417" spread="2.287"/>
                    <measurement group_id="O3" value="78.02" spread="28.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Trough Serum Concentrations of Motavizumab at Day 150</title>
        <time_frame>Day 150</time_frame>
        <population>The PK/immunogenicity population included all subjects in the safety population who did not receive commercial Synagis within 120 days prior to Study Day 0. Additional subjects were excluded from individual time point summaries of the analyses if the correct number of study drug doses were not received prior to the corresponding time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Motavizumab (MEDI-524) Followed by Palivizumab</title>
            <description>2 doses of motavizumab (15 mg/kg, administered as an intramuscular injection once/month) followed by 3 doses of palivizumab (15 mg/kg, administered as an intramuscular injection once/month)</description>
          </group>
          <group group_id="O2">
            <title>Palivizumab Followed by Motavizumab (MEDI-524)</title>
            <description>2 doses of palivizumab (15 mg/kg, administered as an intramuscular injection once/month) followed by 3 doses of motavizumab (15 mg/kg, administered as an intramuscular injection once/month)</description>
          </group>
          <group group_id="O3">
            <title>Motavizumab (MEDI-524) Control</title>
            <description>5 doses of motavizumab (15 mg/kg, administered as an intramuscular injection once/month)</description>
          </group>
        </group_list>
        <measure>
          <title>The Trough Serum Concentrations of Motavizumab at Day 150</title>
          <population>The PK/immunogenicity population included all subjects in the safety population who did not receive commercial Synagis within 120 days prior to Study Day 0. Additional subjects were excluded from individual time point summaries of the analyses if the correct number of study drug doses were not received prior to the corresponding time point.</population>
          <units>μg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="53"/>
                <count group_id="O2" value="54"/>
                <count group_id="O3" value="62"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.801" spread="5.682"/>
                    <measurement group_id="O2" value="93.05" spread="30.97"/>
                    <measurement group_id="O3" value="105.8" spread="37.49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Trough Serum Concentrations of Motavizumab 120-150 Days Post Final Dose</title>
        <time_frame>120-150 days post final dose</time_frame>
        <population>The PK/immunogenicity population included all subjects in the safety population who did not receive commercial Synagis within 120 days prior to Study Day 0. Additional subjects were excluded from individual time point summaries of the analyses if the correct number of study drug doses were not received prior to the corresponding time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Motavizumab (MEDI-524) Followed by Palivizumab</title>
            <description>2 doses of motavizumab (15 mg/kg, administered as an intramuscular injection once/month) followed by 3 doses of palivizumab (15 mg/kg, administered as an intramuscular injection once/month)</description>
          </group>
          <group group_id="O2">
            <title>Palivizumab Followed by Motavizumab (MEDI-524)</title>
            <description>2 doses of palivizumab (15 mg/kg, administered as an intramuscular injection once/month) followed by 3 doses of motavizumab (15 mg/kg, administered as an intramuscular injection once/month)</description>
          </group>
          <group group_id="O3">
            <title>Motavizumab (MEDI-524) Control</title>
            <description>5 doses of motavizumab (15 mg/kg, administered as an intramuscular injection once/month)</description>
          </group>
        </group_list>
        <measure>
          <title>The Trough Serum Concentrations of Motavizumab 120-150 Days Post Final Dose</title>
          <population>The PK/immunogenicity population included all subjects in the safety population who did not receive commercial Synagis within 120 days prior to Study Day 0. Additional subjects were excluded from individual time point summaries of the analyses if the correct number of study drug doses were not received prior to the corresponding time point.</population>
          <units>μg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="73"/>
                <count group_id="O2" value="72"/>
                <count group_id="O3" value="83"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.5078" spread="1.031"/>
                    <measurement group_id="O2" value="7.586" spread="5.152"/>
                    <measurement group_id="O3" value="10.01" spread="6.341"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Serum Concentrations of Palivizumab at Day 0</title>
        <time_frame>Day 0</time_frame>
        <population>The PK/immunogenicity population included all subjects in the safety population who did not receive commercial Synagis within 120 days prior to Study Day 0. Additional subjects were excluded from individual time point summaries of the analyses if the correct number of study drug doses were not received prior to the corresponding time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Motavizumab (MEDI-524) Followed by Palivizumab</title>
            <description>2 doses of motavizumab (15 mg/kg, administered as an intramuscular injection once/month) followed by 3 doses of palivizumab (15 mg/kg, administered as an intramuscular injection once/month)</description>
          </group>
          <group group_id="O2">
            <title>Palivizumab Followed by Motavizumab (MEDI-524)</title>
            <description>2 doses of palivizumab (15 mg/kg, administered as an intramuscular injection once/month) followed by 3 doses of motavizumab (15 mg/kg, administered as an intramuscular injection once/month)</description>
          </group>
          <group group_id="O3">
            <title>Motavizumab (MEDI-524) Control</title>
            <description>5 doses of motavizumab (15 mg/kg, administered as an intramuscular injection once/month)</description>
          </group>
        </group_list>
        <measure>
          <title>The Serum Concentrations of Palivizumab at Day 0</title>
          <population>The PK/immunogenicity population included all subjects in the safety population who did not receive commercial Synagis within 120 days prior to Study Day 0. Additional subjects were excluded from individual time point summaries of the analyses if the correct number of study drug doses were not received prior to the corresponding time point.</population>
          <units>μg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="73"/>
                <count group_id="O2" value="72"/>
                <count group_id="O3" value="83"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Values were below the level of detection.</measurement>
                    <measurement group_id="O2" value="NA">Values were below the level of detection.</measurement>
                    <measurement group_id="O3" value="NA">Values were below the level of detection.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Trough Serum Concentrations of Palivizumab at Day 60</title>
        <time_frame>Day 60</time_frame>
        <population>The PK/immunogenicity population included all subjects in the safety population who did not receive commercial Synagis within 120 days prior to Study Day 0. Additional subjects were excluded from individual time point summaries of the analyses if the correct number of study drug doses were not received prior to the corresponding time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Motavizumab (MEDI-524) Followed by Palivizumab</title>
            <description>2 doses of motavizumab (15 mg/kg, administered as an intramuscular injection once/month) followed by 3 doses of palivizumab (15 mg/kg, administered as an intramuscular injection once/month)</description>
          </group>
          <group group_id="O2">
            <title>Palivizumab Followed by Motavizumab (MEDI-524)</title>
            <description>2 doses of palivizumab (15 mg/kg, administered as an intramuscular injection once/month) followed by 3 doses of motavizumab (15 mg/kg, administered as an intramuscular injection once/month)</description>
          </group>
          <group group_id="O3">
            <title>Motavizumab (MEDI-524) Control</title>
            <description>5 doses of motavizumab (15 mg/kg, administered as an intramuscular injection once/month)</description>
          </group>
        </group_list>
        <measure>
          <title>The Trough Serum Concentrations of Palivizumab at Day 60</title>
          <population>The PK/immunogenicity population included all subjects in the safety population who did not receive commercial Synagis within 120 days prior to Study Day 0. Additional subjects were excluded from individual time point summaries of the analyses if the correct number of study drug doses were not received prior to the corresponding time point.</population>
          <units>μg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="66"/>
                <count group_id="O2" value="66"/>
                <count group_id="O3" value="69"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.103" spread="6.907"/>
                    <measurement group_id="O2" value="87.37" spread="17.41"/>
                    <measurement group_id="O3" value="8.795" spread="6.578"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Trough Serum Concentrations of Palivizumab at Day 150</title>
        <time_frame>Day 150</time_frame>
        <population>The PK/immunogenicity population included all subjects in the safety population who did not receive commercial Synagis within 120 days prior to Study Day 0. Additional subjects were excluded from individual time point summaries of the analyses if the correct number of study drug doses were not received prior to the corresponding time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Motavizumab (MEDI-524) Followed by Palivizumab</title>
            <description>2 doses of motavizumab (15 mg/kg, administered as an intramuscular injection once/month) followed by 3 doses of palivizumab (15 mg/kg, administered as an intramuscular injection once/month)</description>
          </group>
          <group group_id="O2">
            <title>Palivizumab Followed by Motavizumab (MEDI-524)</title>
            <description>2 doses of palivizumab (15 mg/kg, administered as an intramuscular injection once/month) followed by 3 doses of motavizumab (15 mg/kg, administered as an intramuscular injection once/month)</description>
          </group>
          <group group_id="O3">
            <title>Motavizumab (MEDI-524) Control</title>
            <description>5 doses of motavizumab (15 mg/kg, administered as an intramuscular injection once/month)</description>
          </group>
        </group_list>
        <measure>
          <title>The Trough Serum Concentrations of Palivizumab at Day 150</title>
          <population>The PK/immunogenicity population included all subjects in the safety population who did not receive commercial Synagis within 120 days prior to Study Day 0. Additional subjects were excluded from individual time point summaries of the analyses if the correct number of study drug doses were not received prior to the corresponding time point.</population>
          <units>μg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="52"/>
                <count group_id="O2" value="54"/>
                <count group_id="O3" value="60"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="107.4" spread="30.21"/>
                    <measurement group_id="O2" value="22.89" spread="5.631"/>
                    <measurement group_id="O3" value="12.99" spread="7.472"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Trough Serum Concentrations of Palivizumab at 120-150 Days Post Final Dose</title>
        <time_frame>120-150 days post final dose</time_frame>
        <population>The PK/immunogenicity population included all subjects in the safety population who did not receive commercial Synagis within 120 days prior to Study Day 0. Additional subjects were excluded from individual time point summaries of the analyses if the correct number of study drug doses were not received prior to the corresponding time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Motavizumab (MEDI-524) Followed by Palivizumab</title>
            <description>2 doses of motavizumab (15 mg/kg, administered as an intramuscular injection once/month) followed by 3 doses of palivizumab (15 mg/kg, administered as an intramuscular injection once/month)</description>
          </group>
          <group group_id="O2">
            <title>Palivizumab Followed by Motavizumab (MEDI-524)</title>
            <description>2 doses of palivizumab (15 mg/kg, administered as an intramuscular injection once/month) followed by 3 doses of motavizumab (15 mg/kg, administered as an intramuscular injection once/month)</description>
          </group>
          <group group_id="O3">
            <title>Motavizumab (MEDI-524) Control</title>
            <description>5 doses of motavizumab (15 mg/kg, administered as an intramuscular injection once/month)</description>
          </group>
        </group_list>
        <measure>
          <title>The Trough Serum Concentrations of Palivizumab at 120-150 Days Post Final Dose</title>
          <population>The PK/immunogenicity population included all subjects in the safety population who did not receive commercial Synagis within 120 days prior to Study Day 0. Additional subjects were excluded from individual time point summaries of the analyses if the correct number of study drug doses were not received prior to the corresponding time point.</population>
          <units>μg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="72"/>
                <count group_id="O2" value="71"/>
                <count group_id="O3" value="81"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.667" spread="7.719"/>
                    <measurement group_id="O2" value="NA">Values were below the level of detection.</measurement>
                    <measurement group_id="O3" value="NA">Values were below the level of detection.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Immunogenicity of Motavizumab at Day 0</title>
        <description>Number of subjects with detected anti-motavivumab antibodies are reported; defined as a titer with a dilution value of greater than or equal to 1:10.</description>
        <time_frame>Day 0</time_frame>
        <population>The PK/immunogenicity population included all subjects in the safety population who did not receive commercial Synagis within 120 days prior to Study Day 0. Additional subjects were excluded from individual time point summaries of the analyses if the correct number of study drug doses were not received prior to the corresponding time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Motavizumab (MEDI-524) Followed by Palivizumab</title>
            <description>2 doses of motavizumab (15 mg/kg, administered as an intramuscular injection once/month) followed by 3 doses of palivizumab (15 mg/kg, administered as an intramuscular injection once/month)</description>
          </group>
          <group group_id="O2">
            <title>Palivizumab Followed by Motavizumab (MEDI-524)</title>
            <description>2 doses of palivizumab (15 mg/kg, administered as an intramuscular injection once/month) followed by 3 doses of motavizumab (15 mg/kg, administered as an intramuscular injection once/month)</description>
          </group>
          <group group_id="O3">
            <title>Motavizumab (MEDI-524) Control</title>
            <description>5 doses of motavizumab (15 mg/kg, administered as an intramuscular injection once/month)</description>
          </group>
        </group_list>
        <measure>
          <title>The Immunogenicity of Motavizumab at Day 0</title>
          <description>Number of subjects with detected anti-motavivumab antibodies are reported; defined as a titer with a dilution value of greater than or equal to 1:10.</description>
          <population>The PK/immunogenicity population included all subjects in the safety population who did not receive commercial Synagis within 120 days prior to Study Day 0. Additional subjects were excluded from individual time point summaries of the analyses if the correct number of study drug doses were not received prior to the corresponding time point.</population>
          <units>participants with detected antibody</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="77"/>
                <count group_id="O2" value="80"/>
                <count group_id="O3" value="89"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Immunogenicity of Motavizumab at Day 60</title>
        <description>Number of subjects with detected anti-motavivumab antibodies are reported; defined as a titer with a dilution value of greater than or equal to 1:10.</description>
        <time_frame>Day 60</time_frame>
        <population>The PK/immunogenicity population included all subjects in the safety population who did not receive commercial Synagis within 120 days prior to Study Day 0. Additional subjects were excluded from individual time point summaries of the analyses if the correct number of study drug doses were not received prior to the corresponding time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Motavizumab (MEDI-524) Followed by Palivizumab</title>
            <description>2 doses of motavizumab (15 mg/kg, administered as an intramuscular injection once/month) followed by 3 doses of palivizumab (15 mg/kg, administered as an intramuscular injection once/month)</description>
          </group>
          <group group_id="O2">
            <title>Palivizumab Followed by Motavizumab (MEDI-524)</title>
            <description>2 doses of palivizumab (15 mg/kg, administered as an intramuscular injection once/month) followed by 3 doses of motavizumab (15 mg/kg, administered as an intramuscular injection once/month)</description>
          </group>
          <group group_id="O3">
            <title>Motavizumab (MEDI-524) Control</title>
            <description>5 doses of motavizumab (15 mg/kg, administered as an intramuscular injection once/month)</description>
          </group>
        </group_list>
        <measure>
          <title>The Immunogenicity of Motavizumab at Day 60</title>
          <description>Number of subjects with detected anti-motavivumab antibodies are reported; defined as a titer with a dilution value of greater than or equal to 1:10.</description>
          <population>The PK/immunogenicity population included all subjects in the safety population who did not receive commercial Synagis within 120 days prior to Study Day 0. Additional subjects were excluded from individual time point summaries of the analyses if the correct number of study drug doses were not received prior to the corresponding time point.</population>
          <units>participants with detected antibody</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="76"/>
                <count group_id="O2" value="82"/>
                <count group_id="O3" value="90"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Immunogenicity of Motavizumab at Day 150</title>
        <description>Number of subjects with detected anti-motavivumab antibodies are reported; defined as a titer with a dilution value of greater than or equal to 1:10.</description>
        <time_frame>Day 150</time_frame>
        <population>The PK/immunogenicity population included all subjects in the safety population who did not receive commercial Synagis within 120 days prior to Study Day 0. Additional subjects were excluded from individual time point summaries of the analyses if the correct number of study drug doses were not received prior to the corresponding time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Motavizumab (MEDI-524) Followed by Palivizumab</title>
            <description>2 doses of motavizumab (15 mg/kg, administered as an intramuscular injection once/month) followed by 3 doses of palivizumab (15 mg/kg, administered as an intramuscular injection once/month)</description>
          </group>
          <group group_id="O2">
            <title>Palivizumab Followed by Motavizumab (MEDI-524)</title>
            <description>2 doses of palivizumab (15 mg/kg, administered as an intramuscular injection once/month) followed by 3 doses of motavizumab (15 mg/kg, administered as an intramuscular injection once/month)</description>
          </group>
          <group group_id="O3">
            <title>Motavizumab (MEDI-524) Control</title>
            <description>5 doses of motavizumab (15 mg/kg, administered as an intramuscular injection once/month)</description>
          </group>
        </group_list>
        <measure>
          <title>The Immunogenicity of Motavizumab at Day 150</title>
          <description>Number of subjects with detected anti-motavivumab antibodies are reported; defined as a titer with a dilution value of greater than or equal to 1:10.</description>
          <population>The PK/immunogenicity population included all subjects in the safety population who did not receive commercial Synagis within 120 days prior to Study Day 0. Additional subjects were excluded from individual time point summaries of the analyses if the correct number of study drug doses were not received prior to the corresponding time point.</population>
          <units>participants with detected antibody</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="73"/>
                <count group_id="O2" value="75"/>
                <count group_id="O3" value="84"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Immunogenicity of Motavizumab at 120 to 150 Days Post Final Dose</title>
        <description>Number of subjects with detected anti-motavivumab antibodies are reported; defined as a titer with a dilution value of greater than or equal to 1:10.</description>
        <time_frame>120 - 150 days post final dose</time_frame>
        <population>The PK/immunogenicity population included all subjects in the safety population who did not receive commercial Synagis within 120 days prior to Study Day 0. Additional subjects were excluded from individual time point summaries of the analyses if the correct number of study drug doses were not received prior to the corresponding time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Motavizumab (MEDI-524) Followed by Palivizumab</title>
            <description>2 doses of motavizumab (15 mg/kg, administered as an intramuscular injection once/month) followed by 3 doses of palivizumab (15 mg/kg, administered as an intramuscular injection once/month)</description>
          </group>
          <group group_id="O2">
            <title>Palivizumab Followed by Motavizumab (MEDI-524)</title>
            <description>2 doses of palivizumab (15 mg/kg, administered as an intramuscular injection once/month) followed by 3 doses of motavizumab (15 mg/kg, administered as an intramuscular injection once/month)</description>
          </group>
          <group group_id="O3">
            <title>Motavizumab (MEDI-524) Control</title>
            <description>5 doses of motavizumab (15 mg/kg, administered as an intramuscular injection once/month)</description>
          </group>
        </group_list>
        <measure>
          <title>The Immunogenicity of Motavizumab at 120 to 150 Days Post Final Dose</title>
          <description>Number of subjects with detected anti-motavivumab antibodies are reported; defined as a titer with a dilution value of greater than or equal to 1:10.</description>
          <population>The PK/immunogenicity population included all subjects in the safety population who did not receive commercial Synagis within 120 days prior to Study Day 0. Additional subjects were excluded from individual time point summaries of the analyses if the correct number of study drug doses were not received prior to the corresponding time point.</population>
          <units>participants with detected antibody</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="75"/>
                <count group_id="O2" value="74"/>
                <count group_id="O3" value="84"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Immunogenicity of Motavizumab at Any Time</title>
        <description>Number of subjects with detected anti-motavivumab antibodies are reported; defined as a titer with a dilution value of greater than or equal to 1:10.</description>
        <time_frame>At any time</time_frame>
        <population>The PK/immunogenicity population included all subjects in the safety population who did not receive commercial Synagis within 120 days prior to Study Day 0. Additional subjects were excluded from individual time point summaries of the analyses if the correct number of study drug doses were not received prior to the corresponding time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Motavizumab (MEDI-524) Followed by Palivizumab</title>
            <description>2 doses of motavizumab (15 mg/kg, administered as an intramuscular injection once/month) followed by 3 doses of palivizumab (15 mg/kg, administered as an intramuscular injection once/month)</description>
          </group>
          <group group_id="O2">
            <title>Palivizumab Followed by Motavizumab (MEDI-524)</title>
            <description>2 doses of palivizumab (15 mg/kg, administered as an intramuscular injection once/month) followed by 3 doses of motavizumab (15 mg/kg, administered as an intramuscular injection once/month)</description>
          </group>
          <group group_id="O3">
            <title>Motavizumab (MEDI-524) Control</title>
            <description>5 doses of motavizumab (15 mg/kg, administered as an intramuscular injection once/month)</description>
          </group>
        </group_list>
        <measure>
          <title>The Immunogenicity of Motavizumab at Any Time</title>
          <description>Number of subjects with detected anti-motavivumab antibodies are reported; defined as a titer with a dilution value of greater than or equal to 1:10.</description>
          <population>The PK/immunogenicity population included all subjects in the safety population who did not receive commercial Synagis within 120 days prior to Study Day 0. Additional subjects were excluded from individual time point summaries of the analyses if the correct number of study drug doses were not received prior to the corresponding time point.</population>
          <units>participants with detected antibody</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="79"/>
                <count group_id="O2" value="83"/>
                <count group_id="O3" value="91"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Immunogenicity of Palivizumab at Day 0</title>
        <description>Number of subjects with detected anti-palivizumab antibodies are reported; defined as a titer with a dilution value of greater than or equal to 1:10.</description>
        <time_frame>Day 0</time_frame>
        <population>The PK/immunogenicity population included all subjects in the safety population who did not receive commercial Synagis within 120 days prior to Study Day 0. Additional subjects were excluded from individual time point summaries of the analyses if the correct number of study drug doses were not received prior to the corresponding time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Motavizumab (MEDI-524) Followed by Palivizumab</title>
            <description>2 doses of motavizumab (15 mg/kg, administered as an intramuscular injection once/month) followed by 3 doses of palivizumab (15 mg/kg, administered as an intramuscular injection once/month)</description>
          </group>
          <group group_id="O2">
            <title>Palivizumab Followed by Motavizumab (MEDI-524)</title>
            <description>2 doses of palivizumab (15 mg/kg, administered as an intramuscular injection once/month) followed by 3 doses of motavizumab (15 mg/kg, administered as an intramuscular injection once/month)</description>
          </group>
          <group group_id="O3">
            <title>Motavizumab (MEDI-524) Control</title>
            <description>5 doses of motavizumab (15 mg/kg, administered as an intramuscular injection once/month)</description>
          </group>
        </group_list>
        <measure>
          <title>The Immunogenicity of Palivizumab at Day 0</title>
          <description>Number of subjects with detected anti-palivizumab antibodies are reported; defined as a titer with a dilution value of greater than or equal to 1:10.</description>
          <population>The PK/immunogenicity population included all subjects in the safety population who did not receive commercial Synagis within 120 days prior to Study Day 0. Additional subjects were excluded from individual time point summaries of the analyses if the correct number of study drug doses were not received prior to the corresponding time point.</population>
          <units>participants with detected antibody</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="76"/>
                <count group_id="O2" value="78"/>
                <count group_id="O3" value="86"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Immunogenicity of Palivizumab at Day 60</title>
        <description>Number of subjects with detected anti-palivizumab antibodies are reported; defined as a titer with a dilution value of greater than or equal to 1:10.</description>
        <time_frame>Day 60</time_frame>
        <population>The PK/immunogenicity population included all subjects in the safety population who did not receive commercial Synagis within 120 days prior to Study Day 0. Additional subjects were excluded from individual time point summaries of the analyses if the correct number of study drug doses were not received prior to the corresponding time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Motavizumab (MEDI-524) Followed by Palivizumab</title>
            <description>2 doses of motavizumab (15 mg/kg, administered as an intramuscular injection once/month) followed by 3 doses of palivizumab (15 mg/kg, administered as an intramuscular injection once/month)</description>
          </group>
          <group group_id="O2">
            <title>Palivizumab Followed by Motavizumab (MEDI-524)</title>
            <description>2 doses of palivizumab (15 mg/kg, administered as an intramuscular injection once/month) followed by 3 doses of motavizumab (15 mg/kg, administered as an intramuscular injection once/month)</description>
          </group>
          <group group_id="O3">
            <title>Motavizumab (MEDI-524) Control</title>
            <description>5 doses of motavizumab (15 mg/kg, administered as an intramuscular injection once/month)</description>
          </group>
        </group_list>
        <measure>
          <title>The Immunogenicity of Palivizumab at Day 60</title>
          <description>Number of subjects with detected anti-palivizumab antibodies are reported; defined as a titer with a dilution value of greater than or equal to 1:10.</description>
          <population>The PK/immunogenicity population included all subjects in the safety population who did not receive commercial Synagis within 120 days prior to Study Day 0. Additional subjects were excluded from individual time point summaries of the analyses if the correct number of study drug doses were not received prior to the corresponding time point.</population>
          <units>participants with detected antibody</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="76"/>
                <count group_id="O2" value="82"/>
                <count group_id="O3" value="89"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Immunogenicity of Palivizumab at Day 150</title>
        <description>Number of subjects with detected anti-palivizumab antibodies are reported; defined as a titer with a dilution value of greater than or equal to 1:10.</description>
        <time_frame>Day 150</time_frame>
        <population>The PK/immunogenicity population included all subjects in the safety population who did not receive commercial Synagis within 120 days prior to Study Day 0. Additional subjects were excluded from individual time point summaries of the analyses if the correct number of study drug doses were not received prior to the corresponding time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Motavizumab (MEDI-524) Followed by Palivizumab</title>
            <description>2 doses of motavizumab (15 mg/kg, administered as an intramuscular injection once/month) followed by 3 doses of palivizumab (15 mg/kg, administered as an intramuscular injection once/month)</description>
          </group>
          <group group_id="O2">
            <title>Palivizumab Followed by Motavizumab (MEDI-524)</title>
            <description>2 doses of palivizumab (15 mg/kg, administered as an intramuscular injection once/month) followed by 3 doses of motavizumab (15 mg/kg, administered as an intramuscular injection once/month)</description>
          </group>
          <group group_id="O3">
            <title>Motavizumab (MEDI-524) Control</title>
            <description>5 doses of motavizumab (15 mg/kg, administered as an intramuscular injection once/month)</description>
          </group>
        </group_list>
        <measure>
          <title>The Immunogenicity of Palivizumab at Day 150</title>
          <description>Number of subjects with detected anti-palivizumab antibodies are reported; defined as a titer with a dilution value of greater than or equal to 1:10.</description>
          <population>The PK/immunogenicity population included all subjects in the safety population who did not receive commercial Synagis within 120 days prior to Study Day 0. Additional subjects were excluded from individual time point summaries of the analyses if the correct number of study drug doses were not received prior to the corresponding time point.</population>
          <units>participants with detected antibody</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="73"/>
                <count group_id="O2" value="75"/>
                <count group_id="O3" value="84"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Immunogenicity of Palivizumab at 120 to 150 Days Post Final Dose</title>
        <description>Number of subjects with detected anti-palivizumab antibodies are reported; defined as a titer with a dilution value of greater than or equal to 1:10.</description>
        <time_frame>120 - 150 days post final pose</time_frame>
        <population>The PK/immunogenicity population included all subjects in the safety population who did not receive commercial Synagis within 120 days prior to Study Day 0. Additional subjects were excluded from individual time point summaries of the analyses if the correct number of study drug doses were not received prior to the corresponding time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Motavizumab (MEDI-524) Followed by Palivizumab</title>
            <description>2 doses of motavizumab (15 mg/kg, administered as an intramuscular injection once/month) followed by 3 doses of palivizumab (15 mg/kg, administered as an intramuscular injection once/month)</description>
          </group>
          <group group_id="O2">
            <title>Palivizumab Followed by Motavizumab (MEDI-524)</title>
            <description>2 doses of palivizumab (15 mg/kg, administered as an intramuscular injection once/month) followed by 3 doses of motavizumab (15 mg/kg, administered as an intramuscular injection once/month)</description>
          </group>
          <group group_id="O3">
            <title>Motavizumab (MEDI-524) Control</title>
            <description>5 doses of motavizumab (15 mg/kg, administered as an intramuscular injection once/month)</description>
          </group>
        </group_list>
        <measure>
          <title>The Immunogenicity of Palivizumab at 120 to 150 Days Post Final Dose</title>
          <description>Number of subjects with detected anti-palivizumab antibodies are reported; defined as a titer with a dilution value of greater than or equal to 1:10.</description>
          <population>The PK/immunogenicity population included all subjects in the safety population who did not receive commercial Synagis within 120 days prior to Study Day 0. Additional subjects were excluded from individual time point summaries of the analyses if the correct number of study drug doses were not received prior to the corresponding time point.</population>
          <units>participants with detected antibody</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="74"/>
                <count group_id="O2" value="74"/>
                <count group_id="O3" value="83"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Immunogenicity of Palivizumab at Any Time</title>
        <description>Number of subjects with detected anti-palivizumab antibodies are reported; defined as a titer with a dilution value of greater than or equal to 1:10.</description>
        <time_frame>At any time</time_frame>
        <population>The PK/immunogenicity population included all subjects in the safety population who did not receive commercial Synagis within 120 days prior to Study Day 0. Additional subjects were excluded from individual time point summaries of the analyses if the correct number of study drug doses were not received prior to the corresponding time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Motavizumab (MEDI-524) Followed by Palivizumab</title>
            <description>2 doses of motavizumab (15 mg/kg, administered as an intramuscular injection once/month) followed by 3 doses of palivizumab (15 mg/kg, administered as an intramuscular injection once/month)</description>
          </group>
          <group group_id="O2">
            <title>Palivizumab Followed by Motavizumab (MEDI-524)</title>
            <description>2 doses of palivizumab (15 mg/kg, administered as an intramuscular injection once/month) followed by 3 doses of motavizumab (15 mg/kg, administered as an intramuscular injection once/month)</description>
          </group>
          <group group_id="O3">
            <title>Motavizumab (MEDI-524) Control</title>
            <description>5 doses of motavizumab (15 mg/kg, administered as an intramuscular injection once/month)</description>
          </group>
        </group_list>
        <measure>
          <title>The Immunogenicity of Palivizumab at Any Time</title>
          <description>Number of subjects with detected anti-palivizumab antibodies are reported; defined as a titer with a dilution value of greater than or equal to 1:10.</description>
          <population>The PK/immunogenicity population included all subjects in the safety population who did not receive commercial Synagis within 120 days prior to Study Day 0. Additional subjects were excluded from individual time point summaries of the analyses if the correct number of study drug doses were not received prior to the corresponding time point.</population>
          <units>participants with detected antibody</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="82"/>
                <count group_id="O2" value="83"/>
                <count group_id="O3" value="90"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Day 0 - Day 150</time_frame>
      <desc>Safety population</desc>
      <group_list>
        <group group_id="E1">
          <title>Motavizumab (MEDI-524) Followed by Palivizumab</title>
          <description>2 doses of motavizumab (15 mg/kg, administered as an intramuscular injection once/month) followed by 3 doses of palivizumab (15 mg/kg, administered as an intramuscular injection once/month)</description>
        </group>
        <group group_id="E2">
          <title>Palivizumab Followed by Motavizumab (MEDI-524)</title>
          <description>2 doses of palivizumab (15 mg/kg, administered as an intramuscular injection once/month) followed by 3 doses of motavizumab (15 mg/kg, administered as an intramuscular injection once/month)</description>
        </group>
        <group group_id="E3">
          <title>Motavizumab (MEDI-524) Control</title>
          <description>5 doses of motavizumab (15 mg/kg, administered as an intramuscular injection once/month)</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (11.1)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="83"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="83"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="93"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Visual disturbance</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="83"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="93"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>CONSTIPATION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>GASTROOESOPHAGEAL REFLUX DISEASE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="83"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>INFANTILE COLIC</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>INGUINAL HERNIA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="83"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>INTESTINAL OBSTRUCTION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="93"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>BRONCHIOLITIS</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="83"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="83"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>BRONCHITIS</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="83"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>BRONCHITIS VIRAL</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="83"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>CROUP INFECTIOUS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="83"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>GASTROENTERITIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="83"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>LOWER RESPIRATORY TRACT INFECTION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="83"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>PARAINFLUENZAE VIRUS INFECTION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="83"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>PNEUMONIA</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="83"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>PNEUMONIA INFLUENZAL</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="83"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>PNEUMONIA PARAINFLUENZAE VIRAL</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>PNEUMONIA RESPIRATORY SYNCYTIAL VIRAL</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="83"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>RESPIRATORY SYNCYTIAL VIRUS BRONCHIOLIT</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>RESPIRATORY TRACT INFECTION VIRAL</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="83"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>SEPSIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="83"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>STAPHYLOCOCCAL SCALDED SKIN SYNDROME</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="83"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>UPPER RESPIRATORY TRACT INFECTION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="83"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>VIRAL INFECTION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="83"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="93"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>LIVER FUNCTION TEST ABNORMAL</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="93"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>APNOEA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="83"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>WHEEZING</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="83"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="93"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>ERYTHEMA MULTIFORME</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="83"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="93"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>2</frequency_threshold>
        <default_vocab>MedDRA (11.1)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="75" subjects_at_risk="83"/>
                <counts group_id="E2" subjects_affected="74" subjects_at_risk="83"/>
                <counts group_id="E3" subjects_affected="83" subjects_at_risk="93"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>ANAEMIA</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="83"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="83"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>ANAEMIA NEONATAL</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="83"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="93"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>CONJUNCTIVITIS</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="83"/>
                <counts group_id="E2" events="11" subjects_affected="11" subjects_at_risk="83"/>
                <counts group_id="E3" events="16" subjects_affected="16" subjects_at_risk="93"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>ABDOMINAL PAIN</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="83"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="83"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>CONSTIPATION</sub_title>
                <counts group_id="E1" events="8" subjects_affected="6" subjects_at_risk="83"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="83"/>
                <counts group_id="E3" events="10" subjects_affected="6" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>DIARRHOEA</sub_title>
                <counts group_id="E1" events="13" subjects_affected="12" subjects_at_risk="83"/>
                <counts group_id="E2" events="15" subjects_affected="13" subjects_at_risk="83"/>
                <counts group_id="E3" events="13" subjects_affected="11" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>FLATULENCE</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="83"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="83"/>
                <counts group_id="E3" events="5" subjects_affected="3" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>GASTROOESOPHAGEAL REFLUX DISEASE</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="83"/>
                <counts group_id="E2" events="9" subjects_affected="7" subjects_at_risk="83"/>
                <counts group_id="E3" events="7" subjects_affected="7" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>INFANTILE COLIC</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E2" events="3" subjects_affected="1" subjects_at_risk="83"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>INGUINAL HERNIA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="83"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>TEETHING</sub_title>
                <counts group_id="E1" events="24" subjects_affected="10" subjects_at_risk="83"/>
                <counts group_id="E2" events="14" subjects_affected="9" subjects_at_risk="83"/>
                <counts group_id="E3" events="27" subjects_affected="16" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>UMBILICAL HERNIA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="83"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="83"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>VOMITING</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="83"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="83"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="93"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>INJECTION SITE ERYTHEMA</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="83"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="83"/>
                <counts group_id="E3" events="13" subjects_affected="8" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>IRRITABILITY</sub_title>
                <counts group_id="E1" events="27" subjects_affected="10" subjects_at_risk="83"/>
                <counts group_id="E2" events="32" subjects_affected="11" subjects_at_risk="83"/>
                <counts group_id="E3" events="43" subjects_affected="11" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>PYREXIA</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="83"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="83"/>
                <counts group_id="E3" events="11" subjects_affected="11" subjects_at_risk="93"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>IMMUNISATION REACTION</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="83"/>
                <counts group_id="E2" events="6" subjects_affected="4" subjects_at_risk="83"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="93"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>BRONCHIOLITIS</sub_title>
                <counts group_id="E1" events="7" subjects_affected="6" subjects_at_risk="83"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="83"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>BRONCHITIS</sub_title>
                <counts group_id="E1" events="21" subjects_affected="14" subjects_at_risk="83"/>
                <counts group_id="E2" events="27" subjects_affected="20" subjects_at_risk="83"/>
                <counts group_id="E3" events="29" subjects_affected="19" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>CANDIDA NAPPY RASH</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="83"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="83"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>CANDIDIASIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="83"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>EAR INFECTION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="83"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>GASTROENTERITIS</sub_title>
                <counts group_id="E1" events="8" subjects_affected="7" subjects_at_risk="83"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="83"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>GASTROENTERITIS ROTAVIRUS</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="83"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>GENITAL CANDIDIASIS</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="83"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="83"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>LARYNGITIS</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="83"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="83"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>LOWER RESPIRATORY TRACT INFECTION</sub_title>
                <counts group_id="E1" events="12" subjects_affected="7" subjects_at_risk="83"/>
                <counts group_id="E2" events="8" subjects_affected="6" subjects_at_risk="83"/>
                <counts group_id="E3" events="11" subjects_affected="6" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>NASOPHARYNGITIS</sub_title>
                <counts group_id="E1" events="35" subjects_affected="25" subjects_at_risk="83"/>
                <counts group_id="E2" events="40" subjects_affected="26" subjects_at_risk="83"/>
                <counts group_id="E3" events="37" subjects_affected="23" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>ORAL CANDIDIASIS</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="83"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="83"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>OTITIS MEDIA</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="83"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="83"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>OTITIS MEDIA ACUTE</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="83"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>PHARYNGITIS</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="83"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="83"/>
                <counts group_id="E3" events="10" subjects_affected="10" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>RASH PUSTULAR</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="83"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>RHINITIS</sub_title>
                <counts group_id="E1" events="12" subjects_affected="10" subjects_at_risk="83"/>
                <counts group_id="E2" events="18" subjects_affected="14" subjects_at_risk="83"/>
                <counts group_id="E3" events="8" subjects_affected="8" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>UPPER RESPIRATORY TRACT INFECTION</sub_title>
                <counts group_id="E1" events="28" subjects_affected="17" subjects_at_risk="83"/>
                <counts group_id="E2" events="22" subjects_affected="15" subjects_at_risk="83"/>
                <counts group_id="E3" events="25" subjects_affected="18" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>URINARY TRACT INFECTION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>VARICELLA</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="83"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="83"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>VIRAL INFECTION</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="83"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="83"/>
                <counts group_id="E3" events="4" subjects_affected="3" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>VIRAL UPPER RESPIRATORY TRACT INFECTION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="83"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="93"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>CONTUSION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="83"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>PROCEDURAL PAIN</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="83"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="93"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>ALANINE AMINOTRANSFERASE INCREASED</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="83"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="83"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>ASPARTATE AMINOTRANSFERASE INCREASED</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="83"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="83"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>BLOOD UREA INCREASED</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="83"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="83"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>CARDIAC MURMUR</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="83"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="83"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="93"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>HYPERTONIA</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="83"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="83"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>PSYCHOMOTOR SKILLS IMPAIRED</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="83"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="93"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>AGITATION</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="83"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="83"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>BREATH HOLDING</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="83"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="93"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>GENITAL RASH</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="83"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="83"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="93"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>BRONCHIAL HYPERREACTIVITY</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>COUGH</sub_title>
                <counts group_id="E1" events="7" subjects_affected="6" subjects_at_risk="83"/>
                <counts group_id="E2" events="5" subjects_affected="4" subjects_at_risk="83"/>
                <counts group_id="E3" events="6" subjects_affected="5" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>NASAL CONGESTION</sub_title>
                <counts group_id="E1" events="8" subjects_affected="7" subjects_at_risk="83"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="83"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>RHINORRHOEA</sub_title>
                <counts group_id="E1" events="12" subjects_affected="3" subjects_at_risk="83"/>
                <counts group_id="E2" events="6" subjects_affected="5" subjects_at_risk="83"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>WHEEZING</sub_title>
                <counts group_id="E1" events="21" subjects_affected="15" subjects_at_risk="83"/>
                <counts group_id="E2" events="11" subjects_affected="8" subjects_at_risk="83"/>
                <counts group_id="E3" events="12" subjects_affected="10" subjects_at_risk="93"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>DERMATITIS ATOPIC</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="83"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="83"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>DERMATITIS DIAPER</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="83"/>
                <counts group_id="E2" events="12" subjects_affected="10" subjects_at_risk="83"/>
                <counts group_id="E3" events="16" subjects_affected="10" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>DRY SKIN</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="83"/>
                <counts group_id="E3" events="6" subjects_affected="4" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>ECZEMA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="83"/>
                <counts group_id="E2" events="7" subjects_affected="5" subjects_at_risk="83"/>
                <counts group_id="E3" events="7" subjects_affected="4" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>ERYTHEMA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="83"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="83"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>RASH</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="83"/>
                <counts group_id="E2" events="6" subjects_affected="5" subjects_at_risk="83"/>
                <counts group_id="E3" events="6" subjects_affected="4" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>RASH ERYTHEMATOUS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="83"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>SEBORRHOEIC DERMATITIS</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="83"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="83"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="93"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>MedImmune has 60 days to review results communications prior to public release and may delete information that compromises ongoing studies or is considered proprietary. This restriction is not intended to compromise the objective scientific integrity of the manuscript, it being understood that results shall be published regardless of outcome. The PIs also agree for data to be presented first as a joint, multi-center publication.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Pamela Griffin</name_or_title>
      <organization>MedImmune</organization>
      <phone>301 398 0000</phone>
      <email>clinicaltrialenquiries@medimmune.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

